SENBEXUS Trademark

Trademark Overview


On Wednesday, August 7, 2024, a trademark application was filed for SENBEXUS with the United States Patent and Trademark Office. The USPTO has given the SENBEXUS trademark a serial number of 98686740. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, September 23, 2025. This trademark is owned by Celgene Corporation. The SENBEXUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease for human use; Antivirals for human use; Biological preparations in the nature of antibodies for medical purposes for human use; Biological preparations for the treatment of cancer for human use; Anticoagulants for human use; Biological preparations in the nature of stem cells for medical purposes for human use; Radiopharmaceutical preparations for the treatment of cancer and solid tumors for human use; Diagnostic radiopharmaceutical preparations for human use; Biological preparations in the nature of diagnostic preparations for medical purposes for human us...
senbexus

General Information


Serial Number98686740
Word MarkSENBEXUS
Filing DateWednesday, August 7, 2024
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, September 23, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 23, 2025

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease for human use; Antivirals for human use; Biological preparations in the nature of antibodies for medical purposes for human use; Biological preparations for the treatment of cancer for human use; Anticoagulants for human use; Biological preparations in the nature of stem cells for medical purposes for human use; Radiopharmaceutical preparations for the treatment of cancer and solid tumors for human use; Diagnostic radiopharmaceutical preparations for human use; Biological preparations in the nature of diagnostic preparations for medical purposes for human use.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 7, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events


Event DateEvent Description
Wednesday, August 7, 2024NEW APPLICATION ENTERED
Saturday, February 22, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 24, 2025ASSIGNED TO EXAMINER
Monday, February 24, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 24, 2025NON-FINAL ACTION E-MAILED
Monday, February 24, 2025NON-FINAL ACTION WRITTEN
Wednesday, May 14, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 14, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 14, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 23, 2025FINAL REFUSAL E-MAILED
Friday, May 23, 2025FINAL REFUSAL WRITTEN
Thursday, August 21, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 21, 2025TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, August 21, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 22, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 17, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 23, 2025PUBLISHED FOR OPPOSITION
Tuesday, September 23, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, May 23, 2025NOTIFICATION OF FINAL REFUSAL EMAILED